SecBot SecBot
SECBOTREPLAY Home › Report › PDSB

PDSB · PDS Biotech reported Q2 2026 EPS of -$0.18, a 42.1% miss vs consensus…

PDS Biotechnology Corp · 8-K filed Aug 13, 2026 at 08:35 ET

At the news

BEARISHIMPACT 7/10

8-K filed Aug 13, 2026 at 08:35 ET

PDS Biotech reported Q2 2026 EPS of -$0.18, a 42.1% miss vs consensus of -$0.13, and announced a strategic refocus to prioritize PDS0301, discontinuing the VERSATILE-003 Phase 3 trial for PDS0101. Cash burned to $5.6M from $21.7M at year-end, with negative working capital of -$5.3M, raising going-concern risk. The pipeline pivot and cash runway depletion are the primary stock-moving events, outweighing the earnings miss for this pre-revenue biotech.

  • Net loss of $9.8M ($0.18/share) for Q2 2026 vs $9.4M ($0.21/share) in Q2 2025
  • EPS of -$0.18 missed consensus of -$0.13 by 42.1%
  • Cash balance fell to $5.6M as of June 30, 2026, from $21.7M at March 31, 2026
  • Working capital turned negative to -$5.3M from positive $18.8M at year-end 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access